NCT02570490View on ClinicalTrials.gov

Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

PHASE3CompletedINTERVENTIONAL
Enrollment

716

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
DRUG

sodium fusidate

DRUG

linezolid

Trial Locations (62)

19103

Philadelphia

21093

Lutherville

29485

Summerville

29720

Lancaster

30909

Augusta

31401

Savannah

31904

Columbus

32713

DeBary

32720

DeLand

32806

Orlando

33014

Miami Lakes

33015

Miami

33021

Hollywood

33126

Doral

Miami

33143

South Miami

33144

Miami

33155

Miami

33166

Doral

33175

Miami

33401

West Palm Beach

38305

Jackson

45219

Cincinnati

48202

Detroit

48703

Royal Oak

57702

Rapid City

59701

Butte

63128

St Louis

68510

Lincoln

70535

Eunice

70714

Baker

77011

Houston

77084

Houston

77093

Houston

77372

Splendora

78229

San Antonio

78629

Gonzales

89109

San Diego

90020

Los Angeles

90620

Buena Park

90623

La Palma

90813

Long Beach

91342

Sylmar

91773

San Dimas

91911

San Diego

91942

La Mesa

San Diego

91950

National City

92056

Oceanside

92114

San Diego

92120

San Diego

92506

Riverside

92708

Fountain Valley

92804

Anaheim

93301

Bakersfield

95204

Stockton

95350

Modesto

02111

Boston

08244

Somers Point

07666

Teaneck

00909-3004

San Juan

00909

San Juan

Sponsors

Lead Sponsor

Arrevus Inc.
All Listed Sponsors
lead

Arrevus Inc.

INDUSTRY

NCT02570490 - Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections | Biotech Hunter | Biotech Hunter